Congress moves to gut price-protection law shielding independent pharmacies

What it does

This bill repeals the Robinson-Patman Act of 1936, a federal law that prohibits manufacturers and wholesalers from offering different prices to competing retailers for the same goods. Repealing it would allow pharmaceutical companies and other suppliers to offer volume discounts or selective pricing to large chains or preferred buyers without legal restriction, potentially lowering costs for some large purchasers but removing protections that smaller retailers and independent pharmacies currently rely on to compete.

Why we flagged it

The bill's sole operative mechanism is the repeal of a price-discrimination statute. This is a direct deregulation measure that removes a constraint on supplier pricing power, not a consumer-protection or public-health reform despite the title's invocation of 'prescription drugs.'

What the text implies

• Title frames repeal as 'restoring' discounts, but the Robinson-Patman Act itself was designed to prevent predatory discounting — repealing it removes protections against below-cost sales that harm small competitors, not barriers to legitimate volume pricing.
• Pharmaceutical industry may use pricing flexibility to consolidate retail distribution, favoring large chains and mail-order/PBM-owned pharmacies over independent community pharmacies.
• Rural and underserved areas dependent on independent pharmacies may face reduced access if those pharmacies cannot compete on price after losing Robinson-Patman protections.
• Repeal does not directly cap or reduce drug prices; it removes a tool small retailers use to challenge discriminatory pricing — the civic benefit claimed in the title is not mechanically guaranteed.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Repeal may lower drug prices for large institutional buyers and consumers served by major chains, but independent pharmacies and small retailers lose legal recourse against predatory pricing, potentially reducing competition and pharmacy access in rural or underserved areas. The net effect on ordinary consumers depends on whether lower prices at large chains offset reduced choice and higher prices at independent pharmacies.

Who stands to gain

• large pharmaceutical manufacturers
• major pharmacy chains (CVS, Walgreens, Walmart)
• pharmacy benefit managers (PBMs)
• large institutional buyers (hospitals, health systems)

Named in the bill

Robinson-Patman Act, 49 Stat. 1526, 15 U.S.C. 13a, pharmaceutical manufacturers, pharmacy retailers, independent pharmacies

Where it stands

• Jun 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 17, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,570,000 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Rand Paul, the sponsor, reported $94,645 in PAC receipts in the 2026 cycle.

• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.